A large-scale cluster-randomized trial in Kwale, Kenya, demonstrated that mass administration of ivermectin to children aged 5–15 reduced new malaria infections by 26% beyond standard bed net use. This study, published in The New England Journal of Medicine under the BOHEMIA project, supports ivermectin as a complementary vector control measure amid rising insecticide resistance and mosquito behavioral adaptations. The trial administered monthly ivermectin doses over three months, offering a promising adjunctive tool in high-burden malaria control.